Atrion Corporation acquired by Nordson Corporation

Nordson Corporation completed its acquisition of Atrion Corporation on August 21, 2024, following the definitive agreement announced on May 28, 2024. The strategic rationale is centered on portfolio expansion within Nordson Medical. Atrion adds proprietary infusion fluid delivery and niche cardiovascular technologies, broadening Nordson’s exposure to adjacent end markets and strengthening its offering in higher-growth medical applications. The combination is highly complementary from both a product and customer standpoint, while also benefiting from Atrion’s FDA-registered manufacturing footprint and patent portfolio. This creates a more comprehensive platform with meaningful cross-sell and integration potential. From a value creation perspective, the transaction supports Nordson’s long-term growth framework by increasing exposure to secular healthcare demand, recurring single-use consumables, and OEM outsourcing trends. Management also highlighted anticipated operational synergies over the first two years of ownership, which should enhance the deal’s attractiveness and support margin expansion over time.

The acquisition of Atrion Corporation is part of the growth strategy of Nordson Corporation, which already has several external growth operations under its belt, notably Gruppo Arag in 2023.